Consumer Packaged Goods, Food & Household Brands · Advertiser / Brand
Kenvue
Public consumer health brand owner spun out from Johnson & Johnson.
Available information varies by company and source.
Profile record updated:
Company facts
- Official name
- Kenvue Inc.
- Entity type
- COMPANY
- Founded
- 2023
- Headquarters
- 1 Kenvue Way, Summit, NJ 07901, United States
- Company size
- >5,000
- Market cluster / sector
- Consumer Packaged Goods, Food & Household Brands
- Market role
- Advertiser / Brand
- Ticker
- KVUE
- Official website
- kenvue.com
What Kenvue does
Kenvue operates a scaled branded consumer health model. It develops, owns, markets, and distributes consumer health products, then monetises demand through wholesale and retail sell-through across physical and digital commerce channels. Value is created through brand ownership, broad distribution, category shelf presence, consumer trust, and repeat purchase behaviour across everyday health and self-care categories.
Category differentiation
Kenvue is a consumer health brand owner, not an adtech, martech, or SaaS platform. It is the standalone public company spun out from Johnson & Johnson, not Johnson & Johnson itself.
Strategic context
AI-supported assessment from the existing company research; distinguish interpretation from sourced facts.
Kenvue Inc. is a publicly listed consumer health company created through the 2023 separation from Johnson & Johnson. It owns and markets a portfolio of consumer health brands across multiple segments and generates large-scale global sales through retail, pharmacy, e-commerce, and distribution channels. The company operates as a branded consumer goods owner rather than a software or advertising platform. Kenvue makes money by selling packaged consumer health products at scale through channel partners and retail relationships. Its customers are end consumers buying personal health products, while its direct commercial counterparties include retailers, pharmacies, distributors, and e-commerce merchants that stock and resell its portfolio.
Company news briefing
Briefing updated:
Kenvue continues to advance its pending $40 billion acquisition by Kimberly-Clark ahead of its expected late 2026 completion. Alongside structural optimisations via its 'Our Vue Forward' initiative targeting $200 million in annualised savings, the company is expanding its brand portfolio with the launch of Zyrtec's drug-free allergen shield spray. Meanwhile, Kenvue is navigating industry-wide challenges regarding retail media measurement standards highlighted by the ANA, alongside managing public relations fallout and reputational impacts following consumer backlash concerning its Neutrogena subsidiary.
Business model & monetisation
Kenvue monetises through product sales of branded consumer health goods. Commercially, revenue is driven by wholesale supply into retail and pharmacy channels, e-commerce sell-through, and recurring replenishment demand for everyday health products. The dominant pricing mechanism is product unit sales rather than subscriptions, licensing, or advertising.
- Consumer health product sales
- Retail Margin
- Wholesale and distributor sell-in
- One-time Sale
- E-commerce product sales
- Retail Margin
Products & capabilities
No products with linked sources are available in this view.
Unlock Full Intelligence Profile for Kenvue
Get unlimited access to corporate ownership, historical M&A transactions, verified tech stack telemetry, and live market signals in the interactive Knowledge Graph.
Verified Ownership & Corporate Hierarchy
Complete corporate hierarchy traversal, shareholder cap table history, and parent holding links sourced from regulatory filings.
360° Tech Stack & Vendor Telemetry
Technical header bidding configurations, sellers.json registry nodes, CMP disclosures, and direct programmatic supply chains.
Live Market Signals & Executive Briefings
Continuous 24/7 monitoring of material M&A deals, executive shifts, product rollouts, and hiring trends across peer entities.
Competitors & alternatives
Track competitor shifts
Receive automated telemetry on strategic moves, acquisitions, and market share shifts across Kenvue's competitive landscape.
Public consumer healthcare brand owner focused on everyday health.
Public consumer goods owner of household and lifestyle brands.
Consumer goods group selling health, hygiene and nutrition brands.
Global consumer goods company selling household and personal care brands.
Public packaged food brand owner and distributor.
Side-by-side comparisons
Recent recorded signals
Dates refer to the source publication. Older entries are historical context, not evidence of a new event.
8-K Financial Filing Analysis for Kenvue (2026-11-04)
financials · Recorded impact score: 4.5/5
On November 4, 2026, Kenvue LLC (as successor in interest to Kenvue Inc.) announced the settlement of exchange offers and consent solicitations conducted by Kimberly-Clark Corporation. Kimberly-Clark exchanged up to $7.0 billion aggregate principal amount of newly issued notes and cash for outstanding Kenvue senior notes across seven series maturing between 2028 and 2063. In total, approximately $6.38 billion aggregate principal amount of Kenvue Notes were validly tendered, accepted, and retired, leaving approximately $624.0 million outstanding across the seven series. Concurrent with the exchange, the Kenvue Third Supplemental Indenture became operative, substantially eliminating restrictive covenants, certain events of default, SEC reporting obligations, and merger/asset transfer restrictions under the Kenvue Indenture. Additionally, following an NYSE Form 25-NSE filing on November 2, 2026, Kenvue's common stock will be formally delisted on November 12, 2026, marking the post-acquisition integration of Kenvue under Kimberly-Clark.
- Kimberly-Clark accepted and cancelled $6,376,039,000 aggregate principal amount of Kenvue Notes across seven tranches, leaving $623,961,000 outstanding.
- The Third Supplemental Indenture stripped the Kenvue Indenture of substantially all restrictive covenants, SEC reporting requirements, and merger/asset transfer limits.
8-K Financial Filing Analysis for Kenvue (2026-10-30)
financials · Recorded impact score: 3/5
Kenvue Inc. filed a Current Report on Form 8-K under Item 2.02 (Results of Operations and Financial Condition) on October 30, 2026, announcing its financial results for the fiscal third quarter ended September 27, 2026. The full quarterly financial release was furnished as Exhibit 99.1. The filing serves as the formal SEC disclosure vehicle for the company's third-quarter earnings release, signed by Interim Chief Financial Officer and Chief Accounting Officer Heather Howlett.
- Kenvue furnished its fiscal third-quarter financial results for the period ended September 27, 2026 via Exhibit 99.1 on October 30, 2026.
- The filing is furnished pursuant to Item 2.02 and is not deemed filed under Section 18 of the Securities Exchange Act of 1934.
EU Clears Kenvue Deal; Kimberly-Clark to Divest Tampon Brands
M&A · Recorded impact score: 2/5
The European Commission has conditionally approved Kimberly-Clark's $48.8 billion acquisition of Kenvue, a US consumer goods company, on October 14, 2026. To address antitrust concerns, Kimberly-Clark must divest its feminine care brands—Kotex, Lidie, Camelia, and Record—in the European Economic Area (EEA), including trademarks, intellectual property, technical know-how, key employees, and business relationships. Turkish company Dilek (or Dilek Gıda) has been approved as the buyer. The Commission's investigation focused on tampon markets in Czechia, Estonia, and Slovakia, where the merger would have reduced competition. The merger, notified to the EU on August 25, 2026, combines Kimberly-Clark's hygiene products with Kenvue's health and personal care brands such as Neutrogena and Listerine. Kenvue was spun off from Johnson & Johnson in 2023.
- Kimberly-Clark acquires Kenvue for $48.8 billion, with EU approval granted on October 14, 2026, subject to conditions.
- Kimberly-Clark must divest feminine care brands Kotex, Lidie, Camelia, and Record in the EEA.
8-K Financial Filing Analysis for Kenvue (2026-10-13)
financials · Recorded impact score: 4.2/5
On October 9, 2026, Kenvue Inc. entered into a Third Supplemental Indenture with Deutsche Bank Trust Company Americas to amend indentures governing seven series of senior notes due between 2028 and 2063. The execution follows consent solicitations conducted by Kimberly-Clark Corporation in connection with its offer to exchange existing Kenvue notes for up to $7.0 billion aggregate principal amount of new Kimberly-Clark notes and cash, linked to Kimberly-Clark's pending acquisition of Kenvue. The supplemental indenture strips substantially all restrictive covenants, SEC reporting obligations, consolidation/merger restrictions, and certain events of default across the notes, which will become fully operative upon settlement of the exchange offers around the transaction's closing.
- Kenvue executed a Third Supplemental Indenture on October 9, 2026, covering seven senior notes tranches maturing in 2028, 2030, 2032, 2033, 2043, 2053, and 2063.
- The amendments support Kimberly-Clark's exchange offer of up to $7,000,000,000 aggregate principal amount of existing notes into new Kimberly-Clark notes and cash.
Skin360 BIPA Class Action $4.7M Settlement Notice Issued
Privacy · Recorded impact score: 1/5
A proposed class action settlement has been reached in Helene Melzer, et al. v. Johnson & Johnson Consumer Inc. (now Kenvue Brands LLC), pending in the U.S. District Court for the District of New Jersey. The lawsuit alleged that the defendant violated the Illinois Biometric Information Privacy Act (BIPA) by collecting, storing, and profiting from biometric data of individuals who used the Skin360 skin assessment app in Illinois between December 9, 2019, and May 5, 2023. The settlement establishes a $4.7 million fund to compensate class members who submit valid claims. Eligible individuals must file a claim by November 25, 2026. The defendant denies wrongdoing, and the settlement is subject to final court approval at a hearing scheduled for December 17, 2026.
- Settlement fund of $4.7 million established for class members.
- Class covers Illinois residents who used Skin360 app via mobile or web between Dec 9, 2019 and May 5, 2023.
Explore company relationships
Questions about Kenvue
What is Kenvue?
Kenvue is a publicly listed consumer health company that owns and sells branded self-care and personal health products.
Who uses Kenvue?
Consumers use its health products, while retailers, pharmacies, distributors, and e-commerce merchants buy and stock them commercially.
How does Kenvue make money?
Kenvue makes money by selling branded consumer health products through retail, pharmacy, distribution, and e-commerce channels.
Sources & coverage
This profile uses public, official and technically observable information. Missing information does not prove that a product or relationship does not exist. The list below does not imply that every profile statement has been verified.
9 publicly documented primary sources and citations linked across the market graph.
Continue your research on Kenvue
Open additional company details, personal Watchlists and your Strategic Intelligence Agent in Polaris7. It monitors your market daily and delivers tailored briefings with clear strategic context whenever relevant news occurs.
Daily intelligent monitoring · Verified primary sources.
Unlock full intelligence profile, ownership & live market signals